Company news: Pfizer, Novo Nordisk and Lundbeck

Share this article:

Pfizer said it will acquire privately held, specialty pharmaceutical company NextWave Pharmaceuticals for $255 million, with NextWave shareholders eligible to receive additional payments of up to $425 million based on certain sales milestones. NextWave, focused on products for treating ADHD and related CNS disorders, markets Quillivant XR (methylphenidate hydrochloride), a once-daily liquid ADHD medication approved in September. Pfizer entered into an option and merger agreement with NextWave during second-quarter 2012 and made an option payment of $20 million. Pfizer is now exercising its option to acquire the company. Deal terms call for Pfizer to pay $255 million to NextWave shareholders at the close of the transaction, expected during the fourth quarter subject to regulatory approval. Shareholders are eligible to receive additional payments of up to $425 million based on certain sales milestones.

NovoNordisk's ultra long-acting insulins Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) won positive recommendations from the  European Medicines Agency (EMA). Once-daily Tresiba has a duration of action beyond 42 hours, the company said. Ryzodeg can be administered once- or twice-daily. Financial analyst Soren Lontoft, of Sydbank, was quoted by Reuters as estimating peak annual sales of Tresiba at around 22 billion Danish crowns ($3.9 billion) worldwide and around 6 billion in Europe. An approval would challenge Sanofi's 10-year dominance in the long-acting insulin market, Lontoft, said, as quoted by Reuters. Both basal insulin products are headed for a review by US regulators on Nov. 8.

The EMA also rejected a treatment for Alzheimer's disease from Lundbeck called Acrescent, as studies presented did not present a clear benefit. The treatment combines two substances, memantine hydrochloride and donepezil hydrochloride, which already have approval in the EU as separate treatments, the EMA said.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.